A Phase 1 Study to Assess the Feasibility and Safety of Tumor HPV-E6/E7-Targeting T Cell Suspension for Intravenous Infusion (HPV-T) in Patients With HPV-16 Positive Recurrent or Metastatic Solid Tumor

The purpose of this protocol is to evaluate the feasibility and safety of HPV-T in HPV 16 positive recurrent or metastatic solid tumor patients.

开始日期2023-04-13

申办/合作机构

深圳华大基因科技有限公司

[+1]

100 项与 HPV-T(BGI Shenzhen) 相关的临床结果

登录后查看更多信息

100 项与 HPV-T(BGI Shenzhen) 相关的转化医学

登录后查看更多信息

100 项与 HPV-T(BGI Shenzhen) 相关的专利（医药）

登录后查看更多信息

项与 HPV-T(BGI Shenzhen) 相关的文献（医药）

Toxins

Immunochemical Recognition of Bothrops rhombeatus Venom by Two Polyvalent Antivenoms

Article

作者: Sarmiento, Karen ; Zambrano, Jorge ; Galvis, Carlos ; Ramírez-Martínez, Johanna Alejandra ; Molina-Olivares, Álvaro ; Aristizabal, Fabio A ; Castiblanco, Ana Lucía ; Villadiego-Molinares, Marisol Margarita

The protein profile of Bothrops rhombeatus venom was compared to Bothrops asper and Bothrops atrox, and the effectiveness of antivenoms from the National Institute of Health of Colombia (INS) and Antivipmyn-Tri (AVP-T) of Mexico were analyzed. Protein profiles were studied with sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and reverse-phase high-performance liquid chromatography (RP-HPLC). The neutralizing potency and the level of immunochemical recognition of the antivenoms to the venoms were determined using Western blot, affinity chromatography, and enzyme-linked immunosorbent assay (ELISA). Bands of phospholipase A2 (PLA2), metalloproteinases (svMPs) I, II, and III as well as serine proteinases (SPs) in the venom of B. rhombeatus were recognized by SDS-PAGE. With Western blot, both antivenoms showed immunochemical recognition towards PLA2 and svMP. INS showed 94% binding to B. rhombeatus venom and 92% to B. asper while AVP-T showed 90.4% binding to B. rhombeatus venom and 96.6% to B. asper. Both antivenoms showed binding to PLA2 and svMP, with greater specificity of AVP-T towards B. rhombeatus. Antivenom neutralizing capacity was calculated by species and mL of antivenom, finding the following for INS: B. asper 6.6 mgV/mL, B. atrox 5.5 mgV/mL, and B. rhombeatus 1.3 mgV/mL. Meanwhile, for AVP-T, the following neutralizing capacities were found: B. asper 2.7 mgV/mL, B. atrox 2.1 mgV/mL, and B. rhombeatus 1.4 mgV/mL. These results show that both antivenoms presented similarity between calculated neutralizing capacities in our trial, reported in a product summary for the public for the B. asper species; however, this does not apply to the other species tested in this trial.

100 项与 HPV-T(BGI Shenzhen) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HPV16感染	临床1期	中国	深圳华大基因科技有限公司	2023-04-13
人乳头瘤病毒 16 阳性	临床1期	中国	深圳华大基因科技有限公司	2023-04-13
实体瘤	临床1期	中国	深圳华大基因科技有限公司	2023-04-13